España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Daiichi Sankyo Co
DSKYF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$27.31
-1.54
-5.34%
At close: -
Get Report
Comment
Daiichi Sankyo Co (DSKYF) Forecast
News
Earnings
Daiichi Sankyo Co (DSKYF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Daiichi Sankyo Co (OTC:DSKYF) Stock
Daiichi Sankyo Co Stock (OTC: DSKYF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 06, 2024
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Vandana Singh
Monday, October 14, 2024
AstraZeneca And Daiichi Sankyo's Enhertu (Tra...
Benzinga Newsdesk
Monday, September 23, 2024
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Vandana Singh
Tuesday, September 10, 2024
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Vandana Singh
Wednesday, August 07, 2024
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Surbhi Jain
Tuesday, July 30, 2024
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Vandana Singh
Thursday, June 27, 2024
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Vandana Singh
Monday, June 24, 2024
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Shanthi Rexaline
Monday, June 03, 2024
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk
Tuesday, May 28, 2024
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Vandana Singh
Monday, April 29, 2024
Double Good News For AstraZeneca's Breast Cancer Drugs
Vandana Singh
Daiichi Sankyo And AstraZeneca's ENHERTU Show...
Benzinga Newsdesk
Monday, April 08, 2024
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Vandana Singh
Thursday, January 25, 2024
What's Going On With Pfizer Stock Today?
Vandana Singh
Friday, October 20, 2023
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
Nabaparna Bhattacharya
Friday, September 22, 2023
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Vandana Singh
Monday, September 11, 2023
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Vandana Singh
AstraZeneca, Daiichi Sankyo's Datopotamab Der...
Benzinga Newsdesk
Friday, July 21, 2023
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Vandana Singh
Monday, July 03, 2023
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Vandana Singh
Monday, March 20, 2023
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Vandana Singh
Monday, March 06, 2023
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Vandana Singh
Friday, January 13, 2023
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Vandana Singh
Monday, December 19, 2022
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Vandana Singh
Wednesday, December 07, 2022
AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Vandana Singh
Monday, November 14, 2022
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Vandana Singh
Wednesday, September 21, 2022
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Vandana Singh
Monday, August 15, 2022
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Vandana Singh
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Vandana Singh
Friday, August 12, 2022
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Vandana Singh
Tuesday, August 09, 2022
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Vandana Singh
Tuesday, July 19, 2022
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Vandana Singh
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
Vandana Singh
Monday, June 27, 2022
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Vandana Singh
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
Vandana Singh
Monday, June 06, 2022
Morning Brief: Top Financial Stories Dominating on Monday, June 6
Akanksha Bakshi
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
Vandana Singh
Thursday, May 05, 2022
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
Vandana Singh
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Vandana Singh
Wednesday, April 27, 2022
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
Vandana Singh
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Vandana Singh
Tuesday, April 19, 2022
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
Vandana Singh
Monday, April 11, 2022
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
Vandana Singh
Tuesday, February 22, 2022
AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
Vandana Singh
Monday, October 18, 2021
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
Vandana Singh
Monday, September 20, 2021
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
Vandana Singh
Friday, September 17, 2021
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
Vandana Singh
Monday, August 09, 2021
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
Vandana Singh
Thursday, July 08, 2021
Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu
Vandana Singh
Tuesday, June 15, 2021
Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan
Vandana Singh
Show More
